The Oncology Institute(US:TOI) Globenewswire·2026-03-12 20:05Core Insights - The Oncology Institute, Inc. (TOI) reported significant financial growth in Q4 2025, with consolidated revenue increasing by 41.6% to $142.0 million compared to Q4 2024, and gross profit rising by 55.2% to $22.7 million [5][31] - The company achieved a net loss of $7.5 million in Q4 2025, an improvement from a net loss of $13.2 million in the same quarter of the previous year [5][31] - For the full year 2025, TOI's consolidated revenue reached $502.7 million, a 27.8% increase from 2024, while the net loss narrowed to $60.6 million from $64.7 million [5][31] Financial Highlights - Cash flow from operations in Q4 2025 was approximately $3.2 million, attributed to disciplined working capital management and an increase in gross profit margin [5] - Adjusted EBITDA for Q4 2025 was $147 thousand, a significant recovery from a loss of $7.8 million in Q4 2024 [5][31] - As of December 31, 2025, TOI had cash and cash equivalents of $33.6 million [5][31] Operational Developments - TOI expanded its capitated footprint by initiating 9 new capitated contracts in California, Florida, and Nevada, adding approximately 260,000 lives under management [5] - The company ramped up its capitation partnership with Elevance in Florida and initiated agreements with Humana and CarePlus, further expanding its payor partnerships [5] - The company operates 146 affiliated and network clinics across 17 markets, managing approximately 2.0 million lives under value-based contracts [27] Outlook for 2026 - TOI projects revenue between $630 million and $650 million for fiscal year 2026, with expected gross profit ranging from $97 million to $107 million [4][6] - The company anticipates Adjusted EBITDA to be between $(1) million and $(3) million in Q1 2026 due to seasonal factors and drug pricing increases [6] - TOI expects approximately $150 million in capitated revenue in 2026 and aims to achieve full-year positive Adjusted EBITDA [6][9]